Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Dec 14:10:136.
doi: 10.1186/1471-2350-10-136.

Reduced transcription of TCOF1 in adult cells of Treacher Collins syndrome patients

Cibele Masotti  1 , Camila C Ornelas, Alessandra Splendore-Gordonos, Ricardo Moura, Têmis M Félix, Nivaldo Alonso, Anamaria A Camargo, Maria Rita Passos-Bueno
Affiliations

Reduced transcription of TCOF1 in adult cells of Treacher Collins syndrome patients

Cibele Masotti et al. BMC Med Genet. .

Abstract

Background: Treacher Collins syndrome (TCS) is an autosomal dominant craniofacial disorder caused by frameshift deletions or duplications in the TCOF1 gene. These mutations cause premature termination codons, which are predicted to lead to mRNA degradation by nonsense mediated mRNA decay (NMD). Haploinsufficiency of the gene product (treacle) during embryonic development is the proposed molecular mechanism underlying TCS. However, it is still unknown if TCOF1 expression levels are decreased in post-embryonic human cells.

Methods: We have estimated TCOF1 transcript levels through real time PCR in mRNA obtained from leucocytes and mesenchymal cells of TCS patients (n = 23) and controls (n = 18). Mutational screening and analysis of NMD were performed by direct sequencing of gDNA and cDNA, respectively.

Results: All the 23 patients had typical clinical features of the syndrome and pathogenic mutations were detected in 19 of them. We demonstrated that the expression level of TCOF1 is 18-31% lower in patients than in controls (p < 0.05), even if we exclude the patients in whom we did not detect the pathogenic mutation. We also observed that the mutant allele is usually less abundant than the wild type one in mesenchymal cells.

Conclusions: This is the first study to report decreased expression levels of TCOF1 in TCS adult human cells, but it is still unknown if this finding is associated to any phenotype in adulthood. In addition, as we demonstrated that alleles harboring the pathogenic mutations have lower expression, we herein corroborate the current hypothesis of NMD of the mutant transcript as the explanation for diminished levels of TCOF1 expression. Further, considering that TCOF1 deficiency in adult cells could be associated to pathologic clinical findings, it will be important to verify if TCS patients have an impairment in adult stem cell properties, as this can reduce the efficiency of plastic surgery results during rehabilitation of these patients.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Normalized TCOF1 expression levels in TCS patients (circles) and controls (squares). A) TCOF1 expression levels in leucocytes samples from patients (mean ± SEM = 6.846 ± 0.3278) and controls (mean ± SEM = 8.093 ± 0.3587). B) TCOF1 expression levels in mesenchymal cell samples from patients (mean ± SEM = 0.9687 ± 0.1122) and controls (mean ± SEM = 1.414 ± 0.09010). Mean expression value is represented by horizontal lines.
Figure 2
Figure 2
Genomic DNA (gDNA) and complementary DNA (cDNA) sequencing of mesenchymal stem cells samples from four TCS patients. The pathogenic mutation of TCS patients 16, 21, 22, and 23 are c.218_222insAACC (exon 3), c.4344dupA (exon 24), c.431delC (exon 5), and c.4218dupG (exon 23), respectively. gDNA was sequenced with intronic primers and cDNA with exonic primers. Observing all gDNA samples, we can assume that all analyzed individuals are heterozygous for the pathogenic mutation. Analyzing cDNA samples, we could detect the mutant allele expression in TCS 16 and 23; TCS 21 and 22 express only the wild-type allele. Note that even when the mutant allele is expressed (patients TCS16 and TCS23), the peak heights are lower.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Gorlin RJ, Cohen MM, Hennekam RC. Syndromes of the Head and Neck. 4. Oxford: Oxford University Press; 2001. Branchial Arch and oral-Acral Disorders; pp. 790–849.
    1. Dixon MJ, Marres HAM, Edwards SJ, Dixon J, Cremers CWRJ. Treacher Collins syndrome: correlation between clinical and genetic linkage studies. Clin Dysmorphol. 1994;3:96–103. doi: 10.1097/00019605-199404000-00002. - DOI - PubMed
    1. Splendore A, Fanganiello RD, Masotti C, Morganti LSC, Passos-Bueno MR. TCOF1 mutation database: novel mutation in the alternatively spliced exon 6A and update in mutation nomenclature. Hum Mut. 2005;25:429–434. doi: 10.1002/humu.20159. - DOI - PubMed
    1. Gonzales B, Henning D, So RB, Dixon J, Dixon MJ, Valdez BC. The Treacher Collins syndrome (TCOF1) gene product is involved in pre-rRNA methylation. Hum Mol Gene. 2005;14(14):2035–43. doi: 10.1093/hmg/ddi208. - DOI - PubMed
    1. Isaac C, Marsh KL, Panzekas WA, Dixon J, Dixon MJ, Jabs EW, Meier UT. Characterization of the nucleolar gene product, treacle, in Treacher Collins syndrome. Mol Biol Cell. 2001;11:188–192. - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources